Safety study of second eye treatment for Bietti's crystalline dystrophy
Part of Eyes & vision clinical trials.
This study tests the safety of giving the same gene therapy to your second eye, after you already received it in one eye during an earlier study. It aims to see if it's safe and may help improve vision.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have already received the VGR-R01 treatment in one eye as part of an earlier study.
- Your vision in the eye to be treated must be between hand motion and 75 letters on an eye chart.
- You must be able to give informed consent and follow the study rules.
- You must not have other serious eye diseases (like macular degeneration, glaucoma, or diabetic retinopathy) in the study eye.
- You must not have had eye surgery other than cataract surgery in the study eye.
- You must not have conditions like infections, cancer, or immune system problems that could interfere.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial offers compassionate use of the gene therapy ZVS101e for people with Bietti crystalline dystrophy (BCD) who were in the control group of an earlier study. It aims to give extended treatment access to those who didn't receive the experimental therapy before.
This trial tests a new medicine, RRG001, given after vitrectomy surgery for severe diabetic eye disease. It aims to see if the drug is safe and helps prevent vision loss.
This early-stage trial tests a gene therapy aimed at treating inherited retinal dystrophy caused by changes in the RPE65 gene on both copies. It may help slow vision loss or improve eye function, but the study is mainly about safety and learning how the treatment works.
This study tests a gene-editing drug, ZVS203e, injected into one eye to see if it is safe and tolerable for people with retinitis pigmentosa caused by a specific genetic change in the RHO gene. It may help slow vision loss or improve vision, but the main goal is to check safety.
This trial tests a new gene therapy drug (KH631) to see if it is safe and tolerated in people with neovascular age-related macular degeneration (nAMD). It may help your retina problems, but the early goal is mainly to learn about side effects and how the treatment behaves in the eye.
This trial tests an injection (PUMCH-E111) for people with a specific genetic form of inherited retinal dystrophy caused by RLBP1 mutations. It aims to see if the treatment is safe and can help preserve vision.
Hear when a new Bietti Crystalline Dystrophy trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.